We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Turning Stem Cells from Fat into Blood Vessels

By LabMedica International staff writers
Posted on 13 Aug 2012
Print article
Autologous adult stem cells extracted via liposuction from fat tissue can provide the raw materials for growing tissue-engineered blood vessel (TEBV) in the lab, according to a new study.

Researchers at the University of Oklahoma (Norman, USA) first differentiated adipose-derived stem cells into smooth muscle cells (SMCs), and then seeded them onto a flat sheet of the human amniotic membrane--a very thin collagen membrane--used as a biological substrate to fabricate the small-diameter TEBVs. To develop a tubular construct similar to that of a muscular artery's tunica media layer, the cell-seeded sheet was wrapped around a 3-mm removable mandrel with six to seven revolutions. After a two-week static culture period, the fabricated TEBV was assessed for biochemical and mechanical properties.

The researchers examined and compared the contraction of the vessel in response to carbachol--a specific agonist for SMCs--to that of porcine coronary arteries; burst pressure and elastic modulus tests were also conducted. The researchers found that the thickness and architecture of the engineered vessel matched that of a porcine coronary artery in a histological analysis; it also performed better than the porcine vessel for elasticity in a tensile strength test. However, the burst pressure was too low, at about 150 mm Hg, while native tissue withstands 1,000 mm Hg. The problem, according to the researchers, appeared to be that the layers of the rolled-up vessel are not adhering well to one another.

The researchers found that the mechanical integrity of the construct could be further improved by exposure to appropriate physiological conditions in a perfusion bioreactor, and that adipose-derived endothelial cells also could be seeded into the lumen of the construct to prevent platelet adhesion. The study was presented at the American Heart Association Basic Cardiovascular Sciences 2012 scientific sessions, held during July 2012 in New Orleans (LA, USA).

“These liposuction-derived vessels, grown in a lab, could help solve major problems associated with grafting blood vessels from elsewhere in the body or from using artificial blood vessels that are not living tissue,” concluded lead author and study presenter Matthias Nollert, PhD, and colleagues of the school of chemical, biological, and materials engineering. “Our engineered blood vessels have good mechanical properties and we believe they will contract normally when exposed to hormones.”

Related Links:

University of Oklahoma



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.